Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, United States.
Department of Radiology, UT Southwestern Medical Center, Dallas, TX, United States.
Oral Oncol. 2021 Dec;123:105623. doi: 10.1016/j.oraloncology.2021.105623. Epub 2021 Nov 19.
To determine whether cervical matted lymphadenopathy (ML) is associated with outcomes in patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive chemoradiotherapy (CRT).
OPSCC patients treated at our institution with CRT were included (n = 417). ML was defined by three adjacent nodes without an intervening fat plane. Patients were stratified into favorable OPSCC (p16 + with ≤ 10 pack-years smoking history) or unfavorable OPSCC (p16- and/or > 10 pack years). Primary outcomes were overall survival (OS) and progression-free survival (PFS) and the cumulative incidences of regional recurrence (RR) and distant metastasis (DM).
The median follow-up time for the surviving cohort was 49.9 months. In favorable OPSCC (n = 220), there were no significant associations between ML and any outcome. In unfavorable OPSCC (n = 197), ML had a significant negative impact on OS and PFS, with 3-year OS for patients without and with matted nodes at 74% and 56% (HR, 1.61, 95% CI 1.01-2.58). On multivariable Cox regression, patients with ML experienced significantly worsened OS (HR 1.65, 95% CI 1.03-2.65) and PFS (HR 1.94, 95% CI 1.28-2.93). The cumulative incidence of DM was also higher with ML (31% vs. 9%, adjusted HR 3.3, 95% CI 1.71-6.48).
ML carries no prognostic importance in patients with favorable OPSCC. However, ML portends significantly worse outcomes in individuals with HPV-negative disease or a significant smoking history. Thus, ML may help risk-stratify this latter population for treatment intensification, but does not seem to be a contraindication for treatment de-escalation in the former.
确定颈淋巴结融合(ML)是否与接受根治性放化疗(CRT)治疗的口咽鳞癌(OPSCC)患者的结局相关。
纳入在我院接受 CRT 治疗的 OPSCC 患者(n=417)。ML 通过三个无间隔脂肪平面的相邻淋巴结定义。患者分为有利口咽鳞癌(p16+,吸烟史≤10 包年)或不利口咽鳞癌(p16-,和/或吸烟史>10 包年)。主要结局是总生存(OS)和无进展生存(PFS),区域性复发(RR)和远处转移(DM)的累积发生率。
幸存队列的中位随访时间为 49.9 个月。在有利口咽鳞癌(n=220)中,ML 与任何结局均无显著关联。在不利口咽鳞癌(n=197)中,ML 对 OS 和 PFS 有显著的负面影响,无 ML 组和有 ML 组的 3 年 OS 分别为 74%和 56%(HR,1.61,95%CI 1.01-2.58)。多变量 Cox 回归分析显示,有 ML 的患者 OS(HR 1.65,95%CI 1.03-2.65)和 PFS(HR 1.94,95%CI 1.28-2.93)明显恶化。有 ML 组的 DM 累积发生率也更高(31% vs. 9%,调整后的 HR 3.3,95%CI 1.71-6.48)。
ML 在有利口咽鳞癌患者中无预后意义。然而,ML 在 HPV 阴性疾病或大量吸烟史患者中预示着更差的结局。因此,ML 可能有助于对这部分人群进行风险分层以加强治疗,但似乎不是对前者进行治疗降级的禁忌症。